AU2009308124B2 - Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same - Google Patents
Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same Download PDFInfo
- Publication number
- AU2009308124B2 AU2009308124B2 AU2009308124A AU2009308124A AU2009308124B2 AU 2009308124 B2 AU2009308124 B2 AU 2009308124B2 AU 2009308124 A AU2009308124 A AU 2009308124A AU 2009308124 A AU2009308124 A AU 2009308124A AU 2009308124 B2 AU2009308124 B2 AU 2009308124B2
- Authority
- AU
- Australia
- Prior art keywords
- lipoprotein
- insulin resistance
- risk
- patient
- parameters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 233
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 224
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 207
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 201
- 238000000034 method Methods 0.000 title claims abstract description 54
- 238000004590 computer program Methods 0.000 title claims description 10
- 239000002245 particle Substances 0.000 claims abstract description 100
- 230000003247 decreasing effect Effects 0.000 claims abstract description 8
- 238000005259 measurement Methods 0.000 claims description 85
- 238000005481 NMR spectroscopy Methods 0.000 claims description 83
- 239000000523 sample Substances 0.000 claims description 81
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 76
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 74
- 239000008103 glucose Substances 0.000 claims description 74
- 210000002381 plasma Anatomy 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 49
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- 102000004877 Insulin Human genes 0.000 claims description 38
- 108090001061 Insulin Proteins 0.000 claims description 38
- 229940125396 insulin Drugs 0.000 claims description 38
- 206010012601 diabetes mellitus Diseases 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 30
- 235000020925 non fasting Nutrition 0.000 claims description 20
- 239000002131 composite material Substances 0.000 claims description 18
- 230000000875 corresponding effect Effects 0.000 claims description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 8
- 230000002596 correlated effect Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 239000013610 patient sample Substances 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 3
- 238000012502 risk assessment Methods 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 40
- 102000015779 HDL Lipoproteins Human genes 0.000 description 40
- 108010007622 LDL Lipoproteins Proteins 0.000 description 40
- 102000007330 LDL Lipoproteins Human genes 0.000 description 40
- 238000001228 spectrum Methods 0.000 description 38
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 23
- 230000006870 function Effects 0.000 description 14
- 238000004364 calculation method Methods 0.000 description 13
- 239000000470 constituent Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 201000009104 prediabetes syndrome Diseases 0.000 description 9
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 208000001280 Prediabetic State Diseases 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000010183 spectrum analysis Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108010046315 IDL Lipoproteins Proteins 0.000 description 6
- 230000001610 euglycemic effect Effects 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000004066 metabolic change Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 108010002139 very low density lipoprotein triglyceride Proteins 0.000 description 3
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 241001502050 Acis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000000627 alternating current impedance spectroscopy Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10683308P | 2008-10-20 | 2008-10-20 | |
| US61/106,833 | 2008-10-20 | ||
| PCT/US2009/005689 WO2010047767A2 (en) | 2008-10-20 | 2009-10-20 | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009308124A1 AU2009308124A1 (en) | 2010-04-29 |
| AU2009308124B2 true AU2009308124B2 (en) | 2014-12-11 |
Family
ID=42109358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009308124A Expired - Fee Related AU2009308124B2 (en) | 2008-10-20 | 2009-10-20 | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8386187B2 (https=) |
| EP (2) | EP2344890B1 (https=) |
| JP (1) | JP5393798B2 (https=) |
| KR (1) | KR20110086074A (https=) |
| AU (1) | AU2009308124B2 (https=) |
| CA (1) | CA2741034C (https=) |
| WO (1) | WO2010047767A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110086074A (ko) | 2008-10-20 | 2011-07-27 | 리포사이언스, 인크. | 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램 |
| SG10201608139VA (en) * | 2011-06-30 | 2016-11-29 | Liposcience Inc | Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
| TWI596494B (zh) | 2012-03-05 | 2017-08-21 | Ｏｐｋｏ診斷法有限責任公司 | 預測前列腺癌風險及前列腺腺體體積之方法及裝置 |
| US9483612B2 (en) | 2012-04-27 | 2016-11-01 | Liposcience, Inc. | CHD risk stratification evaluations for subjects with high levels of large HDL-P |
| US9361429B2 (en) * | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
| CA2931648C (en) * | 2014-01-06 | 2022-11-29 | Liposcience, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| KR102505543B1 (ko) | 2014-03-28 | 2023-03-02 | 옵코 다이어그노스틱스, 엘엘씨 | 전립선암 진단에 관한 조성물 및 방법 |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| US9952232B2 (en) | 2014-09-11 | 2018-04-24 | Liposcience, Inc. | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| PT3253800T (pt) | 2015-03-27 | 2021-04-28 | Opko Diagnostics Llc | Padrões de antigénio da próstata e suas utilizações |
| KR102539142B1 (ko) | 2016-09-05 | 2023-06-01 | 삼성전자주식회사 | 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치 |
| US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
| US12289368B2 (en) * | 2020-10-29 | 2025-04-29 | Telefonaktiebolaget Lm Ericsson (Publ) | Checking state consistency in a log replication configuration |
| CN113117241B (zh) * | 2021-04-15 | 2022-01-28 | 中国科学院合肥物质科学研究院 | 一种提高胰岛素水平和敏感性的磁场发生装置及其应用 |
| CN115188493A (zh) * | 2022-07-13 | 2022-10-14 | 天津市人民医院 | 一种胰岛素抵抗预测模型的构建系统、方法及应用 |
| WO2024097429A1 (en) * | 2022-11-05 | 2024-05-10 | Texas Tech University System | Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals |
| CN120613144B (zh) * | 2025-05-27 | 2026-02-03 | 中国科学院精密测量科学与技术创新研究院 | 一种基于血液nmr编辑谱的药物敏感度预测方法 |
| CN120280166A (zh) * | 2025-06-10 | 2025-07-08 | 南昌大学第二附属医院 | 术后胰岛素抵抗风险预测模型的构建方法及系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518069B1 (en) * | 1999-04-22 | 2003-02-11 | Liposcience, Inc. | Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders |
| US20050222504A1 (en) * | 2004-04-01 | 2005-10-06 | Otvos James D | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| WO1993003450A1 (en) | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| US6653140B2 (en) * | 1999-02-26 | 2003-11-25 | Liposcience, Inc. | Methods for providing personalized lipoprotein-based risk assessments |
| US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| WO2003012416A1 (en) * | 2001-08-01 | 2003-02-13 | Liposcience, Inc. | Method of determining presence and concentration of lipoprotein x in blood plasma and serum |
| CA2467420A1 (en) * | 2001-11-13 | 2003-05-22 | The Regents Of The University Of California | Ion mobility analysis of biological particles |
| WO2004040407A2 (en) | 2002-10-25 | 2004-05-13 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
| FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
| ES2556164T3 (es) * | 2003-09-23 | 2016-01-13 | The General Hospital Corporation | Cribado de la preeclampsia |
| ES2571929T3 (es) * | 2004-05-26 | 2016-05-27 | Region Nordjylland | Procedimiento para determinar la cantidad de CD36 circulante |
| DE102004026903B4 (de) * | 2004-06-01 | 2006-05-18 | Universität Regensburg | Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür |
| WO2006014678A2 (en) * | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| JP4210855B2 (ja) * | 2004-09-28 | 2009-01-21 | 大塚製薬株式会社 | インスリン抵抗性の評価方法 |
| US7323296B2 (en) * | 2004-10-01 | 2008-01-29 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| EP1645877A1 (en) * | 2004-10-08 | 2006-04-12 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Method for providing a insulin resistance biomarker profile of one or more lipids |
| WO2006110082A1 (en) * | 2005-04-11 | 2006-10-19 | Astrazeneca Ab | A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes. |
| WO2007133593A2 (en) * | 2006-05-10 | 2007-11-22 | Liposcience, Inc. | Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements |
| MX2010000414A (es) * | 2007-07-17 | 2010-04-01 | Metabolon Inc | Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos. |
| US20090191576A1 (en) * | 2008-01-28 | 2009-07-30 | Yuanhong Ma | Method and index for diagnosing insulin resistance |
| KR20110086074A (ko) | 2008-10-20 | 2011-07-27 | 리포사이언스, 인크. | 지질단백질 인슐린 저항성 지표 및 이와 관련된 방법, 시스템 및 이를 생성하기 위한 컴퓨터 프로그램 |
-
2009
- 2009-10-20 KR KR1020117011307A patent/KR20110086074A/ko not_active Ceased
- 2009-10-20 WO PCT/US2009/005689 patent/WO2010047767A2/en not_active Ceased
- 2009-10-20 EP EP09822305.0A patent/EP2344890B1/en active Active
- 2009-10-20 AU AU2009308124A patent/AU2009308124B2/en not_active Expired - Fee Related
- 2009-10-20 US US12/582,259 patent/US8386187B2/en active Active
- 2009-10-20 JP JP2011532094A patent/JP5393798B2/ja active Active
- 2009-10-20 EP EP21190653.2A patent/EP4016105A1/en not_active Ceased
- 2009-10-20 CA CA2741034A patent/CA2741034C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518069B1 (en) * | 1999-04-22 | 2003-02-11 | Liposcience, Inc. | Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders |
| US20050222504A1 (en) * | 2004-04-01 | 2005-10-06 | Otvos James D | NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples |
Non-Patent Citations (2)
| Title |
|---|
| FESTA, A. et al., Circulation, 2005, Vol. 111, Pages 3465-3472 * |
| GARVEY, W. T. et al., Diabetes, 2003, Vol. 52, Pages 453-462 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010047767A2 (en) | 2010-04-29 |
| US8386187B2 (en) | 2013-02-26 |
| WO2010047767A3 (en) | 2010-08-26 |
| CA2741034A1 (en) | 2010-04-29 |
| US20100100334A1 (en) | 2010-04-22 |
| CA2741034C (en) | 2021-06-22 |
| EP2344890A2 (en) | 2011-07-20 |
| EP2344890A4 (en) | 2012-12-26 |
| EP2344890B1 (en) | 2021-08-11 |
| JP5393798B2 (ja) | 2014-01-22 |
| EP4016105A1 (en) | 2022-06-22 |
| KR20110086074A (ko) | 2011-07-27 |
| AU2009308124A1 (en) | 2010-04-29 |
| JP2012506051A (ja) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009308124B2 (en) | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same | |
| EP1171778B1 (en) | Nmr-method for determining the risk of developing type 2 diabetes | |
| JP2024054240A (ja) | 糖尿病への転化を予測する多重マーカリスクパラメータ | |
| Plebani et al. | Hemolysis index: quality indicator or criterion for sample rejection? | |
| WO2013184483A1 (en) | Nmr measurements of glyca | |
| US20240304336A1 (en) | Multiple-Marker Risk Parameters Predictive of Conversion to Diabetes | |
| US20240125719A1 (en) | NMR Quantification of TMAO | |
| HK40077425A (en) | Lipoprotein insulin resistance indexes and related methods, systems and computer program for generating same | |
| HK40055406A (en) | Nmr measurements of glyca for determining coronary heart disease risk | |
| HK1227097B (en) | Multiple-marker risk parameters predictive of conversion to diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |